The first results, published in the British medical journal The Lancet, show that VSV-ZEBOV vaccine demonstrated an efficiency of 100% in the first 10 days for a clinical trial on the ground in Guinea, in more than 4,000 people.
A vaccine against Ebola virus was found to be 100% effective in a clinical trial on the ground in Guinea, more 4,000 people, announced on Friday July 31 the main participants in the project.
“An effective vaccine against the Ebola virus is to reach globally,” he said in a statement the Organization World Health Organization (WHO), which spoke of a “very promising development.”
The first results, published in the British medical journal The Lancet, show that VSV-ZEBOV vaccine demonstrated efficacy of 100% in the first 10 days after administration in an uninfected person but contact with the sick.
The vaccine was developed by the Public Health Agency of Canada (PHAC) and the license was filed by US Merck and NewLink Genetics Corp. The trial was made possible by a major international cooperation in the WHO and experts from Norway, France, Switzerland, USA, UK and Guinea participated.
“If the results are confirmed, this new vaccine could it be the miracle cure for Ebola, and help stem the current epidemic and curb similar epidemics in the future,” he said for his part Borge Brende, Norwegian Minister of Foreign Affairs.
The current Ebola epidemic, which broke out in Guinea in December 2013 and is the most serious in West Africa since the virus was identified in 1976 in central Africa, left 11,279 dead between 27.748 cases, a balance WHO considers even underestimated.
The VSV-ZEBOV vaccine is one of the two most advanced vaccine against the Ebola virus. The other, developed by the British firm GSK (GlaxoSmithKline) and the American Institute of Allergy and Infectious Diseases (NIAID), it is currently being tested in Liberia.
rarl
No comments:
Post a Comment